A fundraiser will be held Thursday for Zachary Ghazali, a 17-year-old LaSalle boy who travels to China for medical treatment of a rare and terminal genetic disorder that attacks the immune system. Ghazali suffers from the incurable Friedreich’s ataxia, which progressively sabotages the co-ordination of the arms and legs, diminishes...
Latest News
Canberra, Australia – A protein in the immune system programmed to protect the body from fungal infections is also responsible for exacerbating the severity of certain autoimmune diseases such as irritable bowel disease (IBS), type 1 diabetes, eczema and other chronic disorders, new research from The Australian National University (ANU)...
MISSOULA, Mont.— FYR Bio (“FYR”), a leader in liquid-biopsy precision medicine for neuro-oncology, today announced a collaboration with NuvOx Therapeutics, Inc. (“NuvOx”) supported by a two-year $1,976,897 Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI). The grant, titled “Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an...
RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended continuation of the pivotal Phase 3 trial (PRESERVE 2), evaluating trilaciclib in combination with gemcitabine and carboplatin for the first line treatment of metastatic triple negative...
Reston, VA — PET imaging with 68Ga-FAPI can more effectively detect and stage pancreatic cancer as compared with 18F-FDG imaging or contrast-enhanced CT, according to new research published in the December issue of The Journal of Nuclear Medicine. In a head-to-head study, 68Ga-FAPI detected more pancreatic tumors on a per-lesion, per-patient, or per-region...
Gabbie Strauss will slowly die from the inside out if a cure for an extremely rare disease can’t be found. The 19-month-old infant may look the picture of perfect health, but sadly that’s not the case. Gabbie is suffering from cystinosis, an incurable metabolic disease where the amino acid cystine...
DUBLIN – For Graves’ Disease Awareness Month in July, Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with world-renowned track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Devers...
BETHESDA, Md.– Gain Therapeutics, Inc., a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage...
Bethesda, Md. — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, announced financial results for the full year ended December 31, 2022, and highlighted recent corporate progress. “We have made significant progress across our pipeline this...
Mechelen, Belgium – Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematology (ASH) Annual Meeting. “The new and updated results from the...